This site is intended for health professionals only
Monday 16 July 2018
Share |

Topic: Diabetes

March 7, 2018
Danish pharmaceutical company Novo Nordisk’s diabetes drug, semaglutide, which could also be used to treat obesity, has passed its first Phase III clinical trial. Semaglutide is taken once daily as a tablet and works by increasing insulin production

As rates of diabetes continue to rise, the hunt for new drugs to tackle the metabolic disease is imperative. In 2014 there were an estimated 422 million people with diabetes, compared to just 108 million in 1980.

Although there are a range of treatment options available for type 2 diabetes, many target the symptoms rather than the root cause and may have adverse side effects. A further difficulty is the close connection between diabetes and obesity, which is causing cases to increase.

September 14, 2017
In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease, compared to basal insulin

According to a new post-hoc analysis presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), people treated with Xultophy® had significantly lower systolic blood pressure, lower total cholesterol as well as lower low-density lipoprotein cholesterol (so-called 'bad cholesterol'), and significant weight changes in favour of Xultophy® compared to people treated with basal insulin (insulin glargine U100 or insulin degludec).

May 19, 2017
The Forum for Injection Technique (FIT) UK has published the latest edition of its UK Injection and Infusion Technique Recommendations

The Forum for Injection Technique (FIT) UK, which provides evidence-based best practice recommendations on diabetes injection technique, has published the latest edition of its UK Injection and Infusion Technique Recommendations, including for the first time a new set of six ‘Golden Rules’.

May 19, 2017
The Forum for Injection Technique (FIT) UK has published the latest edition of its UK Injection and Infusion Technique Recommendations

The Forum for Injection Technique (FIT) UK, which provides evidence-based best practice recommendations on diabetes injection technique, has published the latest edition of its UK Injection and Infusion Technique Recommendations, including for the first time a new set of six ‘Golden Rules’.

September 16, 2016
Results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes 2016

Novo Nordisk has announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9340 adults with type 2 diabetes at high cardiovascular (CV) risk.

September 15, 2015
Patients with type 2 diabetes also reported higher satisfaction with Tresiba® U200 highlighting an overall preference versus insulin glargine U100

New data presented today at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba® (insulin degludec) experienced significantly lower rates of confirmed hypoglycaemia and significantly reduced mean fasting blood glucose compared to those receiving insulin glargine U100. (1) Tresiba® U200 is twice as concentrated as U100, allowing patients to inject up to 160 units in a single injection, rather than in two separate injections.

September 15, 2015
Patients treated with Xultophy® achieved significant improvements in treatment related impact measurements compared to intensifying insulin glargine

Data from the DUAL™ V trial investigating the efficacy and safety of Xultophy® (insulin degludec/liraglutide; IDegLira), in type 2 diabetes patients (T2D) uncontrolled on insulin glargine, were presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting. (1)

September 15, 2015
Patients treated with Xultophy® achieved significant improvements in treatment related impact measurements compared to intensifying insulin glargine

Data from the DUAL™ V trial investigating the efficacy and safety of Xultophy® (insulin degludec/liraglutide; IDegLira), in type 2 diabetes patients (T2D) uncontrolled on insulin glargine, were presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting. (1)

June 26, 2015
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir® (insulin detemir) in children with diabetes as young as one year old

There are an estimated 497,100 children living with type I diabetes globally and incidence is increasing in many countries. (1) Young children with type I diabetes can be difficult to treat as their needs are in constant flux during growth and development, (2) with children aged six and under at greatest risk of severe hypoglycaemia and acute diabetes complications. (3)

June 11, 2015
New data published from the University of Barcelona shows OZURDEX® (dexamethasone 0.7mg intravitreal implant) provides significant improvements in visual acuity, compared to baseline, in patients affected by diabetic macular oedema (DMO). This was observed in patients that had not responded to two or more DMO treatments (refractory, n=40), as well as in those that had not previously received DMO therapy (treatment-naïve, n=36). (1)

New data published from the University of Barcelona shows OZURDEX® (dexamethasone 0.7mg intravitreal implant) provides significant improvements in visual acuity, compared to baseline, in patients affected by diabetic macular oedema (DMO). This was observed in patients that had not responded to two or more DMO treatments (refractory, n=40), as well as in those that had not previously received DMO therapy (treatment-naïve, n=36). (1)

May 29, 2015
Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type II diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance.

Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type II diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance.

Synjardy® combines two products with different mechanisms of action to improve glycaemic control in patients with T2D. Side effects identified with Synjardy® are consistent with known safety profiles of the individual compounds.
 

March 30, 2015
Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin.

Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin.

March 11, 2015
New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.

New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.
 

 

March 11, 2015
New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.

New data presented show that Tresiba® (insulin degludec) improves blood glucose control, reduces the risk of hypoglycaemia and allows for dose reductions in certain patients. (1) These are the first real world data to show the value of insulin degludec in clinical practice across all five countries that prescribe the drug, including the UK, and support insulin degludec clinical trial data.
 

 

February 23, 2015
EKF Diagnostics, the global diagnostics company, announced that it has introduced a new diabetic biomarker test that provides a 2–3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test closes the information gap between daily blood glucose testing and the 2–3 month HbA1c reading. This means that GSP serves as an accurate intermediate marker of glycaemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and haemodialysis. (1)

EKF Diagnostics, the global diagnostics company, announced that it has introduced a new diabetic biomarker test that provides a 2–3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test closes the information gap between daily blood glucose testing and the 2–3 month HbA1c reading. This means that GSP serves as an accurate intermediate marker of glycaemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and haemodialysis. (1)

 

February 23, 2015
EKF Diagnostics, the global diagnostics company, announced that it has introduced a new diabetic biomarker test that provides a 2–3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test closes the information gap between daily blood glucose testing and the 2–3 month HbA1c reading. This means that GSP serves as an accurate intermediate marker of glycaemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and haemodialysis. (1)

EKF Diagnostics, the global diagnostics company, announced that it has introduced a new diabetic biomarker test that provides a 2–3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor® test closes the information gap between daily blood glucose testing and the 2–3 month HbA1c reading. This means that GSP serves as an accurate intermediate marker of glycaemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan and haemodialysis. (1)

 

January 20, 2015
Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2). Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3). The licence extension for Victoza® (liraglutide) increases clinicians’ prescribing options to help patients with both conditions achieve glucose control.
  • Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2).
  • Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3).
November 3, 2014
Novo Nordisk has launched NovoRapid® PumpCart®, the first prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps. This new treatment solution, which contains NovoRapid® (insulin aspart) – a rapid-acting insulin from Novo Nordisk – is expected to make insulin pump therapy more convenient for people with diabetes and their care staff.

Novo Nordisk has launched NovoRapid® PumpCart®, the first prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps. This new treatment solution, which contains NovoRapid® (insulin aspart) – a rapid-acting insulin from Novo Nordisk – is expected to make insulin pump therapy more convenient for people with diabetes and their care staff.

 

September 27, 2013
Sanofi has announced at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, the CE Mark of JuniorSTAR®, a new half unit insulin reusable pen that can be used with Lantus® (insulin glargine), Apidra® (insulin glulisine) or Insuman® (recombinant human insulin).
Sanofi (EURONEXT: SAN and NYSE: SNY) has announced at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, the CE Mark of JuniorSTAR®, a new half unit insulin reusable pen that can be used with Lantus® (insulin glargine), Apidra® (insulin glulisine) or Insuman® (recombinant human insulin).
September 25, 2013
At the annual meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain, Sanofi presented the innovative blood glucose meter MyStar Extra®, the first self-monitoring device that provides robust estimates of the A1c value, a key indicator for long-term glucose control.
At the annual meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain, Sanofi (EURONEXT : SAN and NYSE : SNY), presented the innovative blood glucose meter MyStar Extra®, the first self-monitoring device that provides robust estimates of the A1c value, a key indicator for long-term glucose control.(3,4)
July 25, 2013
EKF Diagnostics, the global in vitro diagnostics business, announces the worldwide launch of the new STAT-Site M ß-HB, following successful CE marking.
EKF Diagnostics, the global in vitro diagnostics business, announces the worldwide launch of the new STAT-Site M ß-HB, following successful CE marking.
June 7, 2013
Siemens Healthcare Diagnostics is raising awareness of the prevalence of diabetes among adolescents to healthcare professionals with the help of Marvel Super Hero, Iron Man.
Siemens Healthcare Diagnostics is raising awareness of the prevalence of diabetes among adolescents to healthcare professionals with the help of Marvel Super Hero, Iron Man. 
November 27, 2012
New analysis from Frost & Sullivan, European Diabetes Diagnostics Market, finds that the market earned revenues of over $3.97 billion in 2011 and estimates this to reach $5.93 billion in 2018.
New analysis from Frost & Sullivan (www.healthcare.frost.com), European Diabetes Diagnostics Market, finds that the market earned revenues of over $3.97 billion in 2011 and estimates this to reach $5.93 billion in 2018. 
The proven efficacy of point-of-care testing (POCT) HbA1c and glucose tests has encouraged their adoption. In most European countries, these tests are a part of routine screening programmes. 
October 19, 2012
EKF Diagnostics, worldwide manufacturer of point-of-care (POC) diagnostic tools, will be introducing two new low cost POC analysers at Medica 2012. The EKF stand (Hall 3 C70) will see the European launch of the new Quo-Lab glycated haemoglobin (HbA1c) analyser for the affordable management of diabetes, as well as a preview of a new strip-based analyser for highly accurate near patient testing of ketosis – the STAT-SiteTM M bHB.
EKF Diagnostics, worldwide manufacturer of point-of-care (POC) diagnostic tools, will be introducing two new low cost POC analysers at Medica 2012.